Related references
Note: Only part of the references are listed.Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities
Khi Pin Chua et al.
CLINICAL CANCER RESEARCH (2021)
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents
Carsten Riether et al.
NATURE MEDICINE (2020)
Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer
Yuta Adachi et al.
CLINICAL CANCER RESEARCH (2020)
A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components
Monique B. Nilsson et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status
Koji Fukuda et al.
CANCER RESEARCH (2019)
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres et al.
ANNALS OF ONCOLOGY (2019)
CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC
Jeffrey H. Becker et al.
CANCER RESEARCH (2019)
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer
Jacqulyne P. Robichaux et al.
NATURE MEDICINE (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Breast cancer stem cells characterized by CD70 expression preferentially metastasize to the lungs
Li Liu et al.
BREAST CANCER (2018)
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer.
Marcelo Vailati Negrao et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
Xiuning Le et al.
CLINICAL CANCER RESEARCH (2018)
CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia
Carsten Riether et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
Sai-Hong Ignatius Ou et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Osimertinib in EGFR T790M-Positive Lung Cancer
Mizuki Nishino et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers
Monique B. Nilsson et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Melanoma-expressed CD70 is involved in invasion and metastasis
Christine Pich et al.
BRITISH JOURNAL OF CANCER (2016)
A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition
Milena P. Mak et al.
CLINICAL CANCER RESEARCH (2016)
TGF-β1 induces erlotinib resistance in non-small cell lung cancer by down-regulating PTEN
Hua Shen et al.
BIOMEDICINE & PHARMACOTHERAPY (2016)
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor et al.
CLINICAL CANCER RESEARCH (2016)
CD70: An emerging target in cancer immunotherapy
J. Jacobs et al.
PHARMACOLOGY & THERAPEUTICS (2015)
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
Matthew J. Niederst et al.
NATURE COMMUNICATIONS (2015)
Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer
Erin M. Tricker et al.
CANCER DISCOVERY (2015)
Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer
Julie Jacobs et al.
ONCOTARGET (2015)
Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition
Steven H. Lin et al.
BMC GENOMICS (2014)
TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma
Z-Z Yang et al.
LEUKEMIA (2014)
ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade
Karen Silence et al.
MABS (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
Limo Chen et al.
NATURE COMMUNICATIONS (2014)
An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Lauren Averett Byers et al.
CLINICAL CANCER RESEARCH (2013)
A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non-Small Cell Lung Cancer Patients
Hao Tang et al.
CLINICAL CANCER RESEARCH (2013)
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistant Disease
Kadoaki Ohashi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
C. Craddock et al.
LEUKEMIA (2013)
Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
Balazs Gyorffy et al.
PLOS ONE (2013)
Distinctive Features of the Differentiated Phenotype and Infiltration of Tumor-Reactive Lymphocytes in Clear Cell Renal Cell Carcinoma
Qiong J. Wang et al.
CANCER RESEARCH (2012)
Soluble CD27 induces IgG production through activation of antigen-primed B cells
L. V. P. Dang et al.
JOURNAL OF INTERNAL MEDICINE (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang et al.
NATURE GENETICS (2012)
Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors
Dalia Ercan et al.
CANCER DISCOVERY (2012)
Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs
Jin-Haeng Chung et al.
LUNG CANCER (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75
M. C. Ryan et al.
BRITISH JOURNAL OF CANCER (2010)
Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with Recurrence
Meera Nanjundan et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1
E. Sanchez-Tillo et al.
ONCOGENE (2010)
TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer
Zhan Yao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer
Lauren Averett Byers et al.
CLINICAL CANCER RESEARCH (2009)
Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology
Martijn A. Nolte et al.
IMMUNOLOGICAL REVIEWS (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The transcription factor ZEB1 (δEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity
K. Aigner et al.
ONCOGENE (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells
Kazunori Kato et al.
EXPERIMENTAL HEMATOLOGY (2007)
Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes
Julia Diegmann et al.
NEOPLASIA (2006)
Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates
CL Law et al.
CANCER RESEARCH (2006)
Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70
A Chahlavi et al.
CANCER RESEARCH (2005)
Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs
QJ Lu et al.
JOURNAL OF IMMUNOLOGY (2005)
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions
W Pao et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
H Shigematsu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Signaling through CD70 regulates B cell activation and IgG production
R Arens et al.
JOURNAL OF IMMUNOLOGY (2004)
Signalling via CD70, a member of the TNF family, regulates T cell functions
P García et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2004)
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository
R Edgar et al.
NUCLEIC ACIDS RESEARCH (2002)
Share Paper
